FOOD AND DRUG ADMINISTRATION ISSUES NOTICE: DERMATOLOGIC AND OPHTHALMIC DRUGS ADVISORY COMMITTEE; NOTICE OF MEETING; ESTABLISHMENT OF A PUBLIC DOCKET; REQUEST FOR COMMENTS-NEW DRUG APPLICATION (NDA) 219694 FOR ATROPINE SULFATE OPHTHALMIC SOLUTION, 0.01%

WASHINGTON, Sept. 25 -- Food and Drug Administration has issued a notice called: Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%.

The notice was published in the Federal Register on Sept. 25 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.

Summary: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting ...